Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
24.96
+0.69 (2.84%)
At close: Aug 13, 2025, 4:00 PM
25.10
+0.14 (0.56%)
After-hours: Aug 13, 2025, 7:21 PM EDT
Janux Therapeutics Revenue
Janux Therapeutics had revenue of $439.00K in the twelve months ending June 30, 2025, down -97.10% year-over-year. In the year 2024, Janux Therapeutics had annual revenue of $10.59M with 30.99% growth.
Revenue (ttm)
$439.00K
Revenue Growth
-97.10%
P/S Ratio
3,322.28
Revenue / Employee
$5,420
Employees
81
Market Cap
1.46B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
JANX News
- 6 days ago - Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 8 days ago - Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Business Wire
- 13 days ago - Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
- 20 days ago - Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day - Business Wire
- 27 days ago - Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 - Business Wire
- 3 months ago - Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer - Business Wire
- 3 months ago - Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 3 months ago - Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates - Business Wire